We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » SANDOZ'S OMNITROPE GETS FDA APPROVAL

SANDOZ'S OMNITROPE GETS FDA APPROVAL

June 1, 2006

After a nearly three-year delay, the FDA has approved Sandoz's generic human growth hormone Omnitrope -- the first follow-on biologic approved under the 505(b)(2) statute of the Federal Food, Drug and Cosmetic Act (FDCA).

The approval comes after a federal court -- in response to a lawsuit filed by Sandoz -- ordered the FDA to issue a decision on Omnitrope (somatropin rdna origin), calling the agency's nearly 1,000-day review "unreasonable." Omnitrope has already been approved for use in the European Union and was launched in Australia in 2005.

The agency said it believes it has the authority to develop a regulatory path for follow-on protein products approved under Section 505 of the FDCA, but emphasized that its approval of Omnitrope does not create a new pathway for approval of follow-on versions of all biologics. Most biologic products are regulated under Section 351 of the Public Health Service Act, but human growth hormone products have historically been regulated under Section 505.

"The approval of Omnitrope in a 505(b)(2) application does not establish a pathway for approval of follow-on products for biological products licensed under section 351 of the Public Health Service Act, nor does it mean that more complex and/or less well understood proteins approved as drugs under the Food, Drug and Cosmetic Act could be approved as follow-on products," the FDA said in a question-and-answer sheet issued after the May 30 approval. "A pathway for approval or licensure of follow-on protein products under the Public Health Service Act would require new legislation."

Biotech companies have asserted that biologic drugs are too complex to reverse-engineer, but generics makers say they have the science to do it.

In a statement, Kathleen Jaeger, president of the Generic Pharmaceutical Association, said, "Although it is our position that the 505(b)(2) FDCA approval process, in conjunction with FDA's authority under the Public Health Act (PHS), already serves as a foundation for the approval of safe and effective generic biopharmaceuticals, we will continue to call on Congress to codify FDA's authority to approve generic biopharmaceuticals under section 351 of PHS." (http://www.fdanews.com/did/5_107/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Hyris T-Cell Test Gains CE-IVD Mark

  • FDA Expands Approval of Bayer’s Nubeqa for Prostate Cancer

  • MicroPort Navibot Receives 510(k) Clearance for Its SkyWalker System

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing